Please download the dossier by clicking on the dossier button x
×

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers

  • US 10,377,803 B1
  • Filed: 04/10/2019
  • Issued: 08/13/2019
  • Est. Priority Date: 07/07/2017
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that present a peptide consisting of the amino acid sequence of VWSNVTPLKF (SEQ ID NO:

  • 2),wherein said cancer is selected from the group consisting of breast cancer (BRCA), cholangiocellular carcinoma (CCC), colorectal cancer (CRC), gallbladder cancer (GBC), glioblastoma (GBM), gastric cancer (GC), hepatocellular carcinoma (HCC), head-and-neck cancer (HNSCC), melanoma (MEL), non-Hodgkin lymphoma (NHL), non-small cell lung cancer (NSCLC), ovarian cancer (OC), esophageal cancer (OSCAR), pancreatic cancer (PAGA), renal cell carcinoma (RCC), small cell lung cancer (SCLC), urinary bladder carcinoma (UBC), and uterine and endometrial cancer (UEC).

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×